AAN 2022 poster: Associations between deflazacort versus prednisone/prednisolone and markers of disease progression in clinically important subgroups of patients with Duchenne muscular dystrophy
Presented at the 2022 AAN Annual Meeting in Seattle, USA, this poster shows results from a study investigating disease progression following treatment with different corticosteroids for Duchenne muscular dystrophy (DMD)
Learn about the study design and baseline characteristics of patients with DMD from 4 clinical trials, who were investigated in this research
Read more on the primary and secondary endpoints used to assess the effect of treatment with different corticosteroids
Find out about the clinical effect of different corticosteroids in patients with DMD, stratified by age, length of corticosteroid use, and stage of disease progression
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at usmedinfo@ptcbio.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-DMD-2200110 | August 2023
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | October 2023
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.